As a preeminent contract research company, Creative Biolabs offers high-quality in vitro diagnostic (IVD) antibody and immunoassay development services targeting a wide range of biomarkers. Here, we focus on the UCH-L1 as a marker of neuronal injury. We are committed to providing the highest quality of custom services and products at the most reasonable prices.
Ubiquitin C-terminal hydrolase-L1 (UCH-L1), also known as neuronal-specific protein gene product 9.5 (PGP9.5) or PARK5, is a 223-amino acid protein (25 kDa). Expressed predominantly in neurons, UCH-L1 is one of the most abundant brain proteins, representing 1 to 2% of total soluble brain protein. Besides, it is also present in cancerous cells originating from tissues that do not normally express UCH-L1, including pancreatic cancer, colorectal cancer, and invasive breast cancer.
On the functional level, UCH-L1 is a multifunctional protein associated with cell survival, axonal transport, and modulation of the ubiquitin-proteasome pathway in neurons. Especially, it is involved in the process of ubiquitination of proteins destined for degradation via the ATP-dependent proteasomal pathway to remove excessive, oxidized, or misfolded proteins. UCH-L1 has been shown to be involved in learning and memory, and its absence in mice because of spontaneous intragenic deletions yields phenotypes with neurological defects. A point mutation (I93M) and a polymorphism (S18Y) in this gene have been shown to associate with Parkinson’s disease.
Fig.1 Proposed functions and regulations of UCH-L1. (Setsuie, 2007)
UCH-L1 concentration has been reported to be elevated in a number of neurological diseases including aneurysmal subarachnoid hemorrhage, traumatic brain injury, stroke, epilepsy, and neonatal hypoxic-ischemic encephalopathy. Remarkably, this neuronal protein can be released from injured neurons and flow into the cerebrospinal fluid (CSF) and circulating blood, meaning that it can be readily detected in both CSF and blood. Moreover, the specificity for neuronal injury augments it a promising neuronal injury biomarker candidate.
As UCH-L1 represents a specific and reliable biomarker of different neurological diseases, appropriate antibodies and sensitive immunoassays can be generated to improve the diagnostic accuracy of the current panel of biomarkers. With years of experience and advanced technology, Creative Biolabs is able to provide a full range of high-quality and cost-effective biomarker-specific antibody development services. We can also offer antibody pairing, antibody conjugation, and diagnostic immunoassay development services of different formats, including ELISAs, lateral flow immunochromatographic assays, immuno-PCR, etc. Please click the links below for more information:
Our hands-on expertise and years of experience in antibody generation allow us to obtain antibodies and diagnostic immunoassays of the best quality for your brilliant projects. Please feel free to contact us for more information and a formal quote.
References
For Research Use Only.
